125 related articles for article (PubMed ID: 10365730)
21. Suppression of Acid Secretion by Lansoprazole and its Effects on Helicobacter pylori. II. Poster presentations from the 2nd International Colloquium on Proton Pump Inhibitors. Houston, Texas, September 29, 1994.
J Clin Gastroenterol; 1995; 20 Suppl 2():S1-135. PubMed ID: 7594319
[No Abstract] [Full Text] [Related]
22. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects.
Timmer W; Ripke H; Kleist P; Ehrlich A; Wieckhorst G; Lücker PW; Fuder H
Methods Find Exp Clin Pharmacol; 1995 Sep; 17(7):489-95. PubMed ID: 8577212
[TBL] [Abstract][Full Text] [Related]
23. [A clinical trial of lansoprazole in the treatment of duodenal ulcer].
Pei Y; Wang B; Chen S
Zhonghua Nei Ke Za Zhi; 1995 Sep; 34(9):606-8. PubMed ID: 8697927
[TBL] [Abstract][Full Text] [Related]
24. Lansoprazole: administration of the contents of a capsule dosage formulation through a nasogastric tube.
Chun AH; Shi HH; Achari R; Dennis S; Cavanaugh JH
Clin Ther; 1996; 18(5):833-42. PubMed ID: 8930427
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
Andersson T
Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
[TBL] [Abstract][Full Text] [Related]
26. Apparent anaphylaxis associated with pantoprazole.
Gratacós L; Soy D; Lluís M; López B; Nicolás JM; Codina C; Nogué S; Ribas J
Am J Health Syst Pharm; 2005 Jul; 62(13):1388-9. PubMed ID: 15972383
[No Abstract] [Full Text] [Related]
27. Lack of interaction between atazanavir and lansoprazole.
Kosel BW; Storey SS; Collier AC
AIDS; 2005 Mar; 19(6):637-8. PubMed ID: 15802988
[No Abstract] [Full Text] [Related]
28. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
[TBL] [Abstract][Full Text] [Related]
29. Lansoprazole for maintenance of remission of erosive oesophagitis.
Freston JW; Jackson RL; Huang B; Ballard ED
Drugs; 2002; 62(8):1173-84. PubMed ID: 12010078
[TBL] [Abstract][Full Text] [Related]
30. Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Kromer W; Horbach S; Lühmann R
Pharmacology; 1999 Aug; 59(2):57-77. PubMed ID: 10450061
[TBL] [Abstract][Full Text] [Related]
31. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously.
Freston J; Chiu YL; Pan WJ; Lukasik N; Täubel J
Am J Gastroenterol; 2001 Jul; 96(7):2058-65. PubMed ID: 11467632
[TBL] [Abstract][Full Text] [Related]
32. Proton pump inhibitor administration via nasogastric tube in pediatric practice: comparative analysis with protocol optimization.
Ponrouch MP; Sautou-Miranda V; Boyer A; Bourdeaux D; Montagner A; Chopineau J
Int J Pharm; 2010 May; 390(2):160-4. PubMed ID: 20132874
[TBL] [Abstract][Full Text] [Related]
33. Determination of lansoprazole and five metabolites in plasma by high-performance liquid chromatography.
Karol MD; Granneman GR; Alexander K
J Chromatogr B Biomed Appl; 1995 Jun; 668(1):182-6. PubMed ID: 7550976
[TBL] [Abstract][Full Text] [Related]
34. A novel option for dosing of proton pump inhibitors: dispersion of lansoprazole orally disintegrating tablet in water via oral syringe.
Gremse DA; Donnelly JR; Kukulka MJ; Lloyd E; Lee C
Aliment Pharmacol Ther; 2004 Jun; 19(11):1211-5. PubMed ID: 15153174
[TBL] [Abstract][Full Text] [Related]
35. [Choice of proton pump inhibitors--does it play any role?].
Hellström PM
Tidsskr Nor Laegeforen; 2004 Oct; 124(20):2620-1. PubMed ID: 15534636
[No Abstract] [Full Text] [Related]
36. An in vitro comparison of different providers to deliver four proton pump inhibitor products through a feeding tube.
Devlin JW; Bakshi A; Bungay K; Olsen KM
Aliment Pharmacol Ther; 2006 Dec; 24(11-12):1603-11. PubMed ID: 17206948
[TBL] [Abstract][Full Text] [Related]
37. Delayed-release lansoprazole plus naproxen.
Curran MP; Wellington K
Drugs; 2004; 64(17):1915-9; discussion 1920-1. PubMed ID: 15329041
[TBL] [Abstract][Full Text] [Related]
38. Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h.
Howden CW; Metz DC; Hunt B; Vakily M; Kukulka M; Amer F; Samra N
Aliment Pharmacol Ther; 2006 Apr; 23(7):975-84. PubMed ID: 16573800
[TBL] [Abstract][Full Text] [Related]
39. Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial.
Russo A; Dattilo M
Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):312-9. PubMed ID: 9476183
[TBL] [Abstract][Full Text] [Related]
40. The clinical importance of proton pump inhibitor pharmacokinetics.
Yacyshyn BR; Thomson AB
Digestion; 2002; 66(2):67-78. PubMed ID: 12428065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
